nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.0332	0.191	CbGeAlD
Zuclopenthixol—HTR6—ganglion—peripheral nervous system neoplasm	0.0151	0.0869	CbGeAlD
Zuclopenthixol—DRD5—ganglion—peripheral nervous system neoplasm	0.0147	0.0846	CbGeAlD
Zuclopenthixol—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.0121	0.0699	CbGeAlD
Zuclopenthixol—DRD1—nerve—peripheral nervous system neoplasm	0.0114	0.0655	CbGeAlD
Zuclopenthixol—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.0113	0.0654	CbGeAlD
Zuclopenthixol—DRD1—ganglion—peripheral nervous system neoplasm	0.0112	0.0647	CbGeAlD
Zuclopenthixol—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.00864	0.0498	CbGeAlD
Zuclopenthixol—HTR2A—pons—peripheral nervous system neoplasm	0.00853	0.0492	CbGeAlD
Zuclopenthixol—DRD2—nerve—peripheral nervous system neoplasm	0.00671	0.0387	CbGeAlD
Zuclopenthixol—DRD2—ganglion—peripheral nervous system neoplasm	0.00663	0.0382	CbGeAlD
Zuclopenthixol—DRD1—brainstem—peripheral nervous system neoplasm	0.00488	0.0281	CbGeAlD
Zuclopenthixol—HTR2A—nerve—peripheral nervous system neoplasm	0.00443	0.0255	CbGeAlD
Zuclopenthixol—HTR2A—ganglion—peripheral nervous system neoplasm	0.00437	0.0252	CbGeAlD
Zuclopenthixol—ADRA1A—brainstem—peripheral nervous system neoplasm	0.00294	0.0169	CbGeAlD
Zuclopenthixol—DRD2—brainstem—peripheral nervous system neoplasm	0.00288	0.0166	CbGeAlD
Zuclopenthixol—HRH1—trigeminal ganglion—peripheral nervous system neoplasm	0.00257	0.0148	CbGeAlD
Zuclopenthixol—ADRA2A—trigeminal ganglion—peripheral nervous system neoplasm	0.00253	0.0146	CbGeAlD
Zuclopenthixol—HTR2A—brainstem—peripheral nervous system neoplasm	0.0019	0.011	CbGeAlD
Zuclopenthixol—CYP2D6—brainstem—peripheral nervous system neoplasm	0.00173	0.00998	CbGeAlD
Zuclopenthixol—Flupentixol—ABCB1—peripheral nervous system neoplasm	0.00158	0.184	CrCbGaD
Zuclopenthixol—ADRA1A—cerebellum—peripheral nervous system neoplasm	0.00145	0.00835	CbGeAlD
Zuclopenthixol—DRD2—cerebellum—peripheral nervous system neoplasm	0.00142	0.00819	CbGeAlD
Zuclopenthixol—ADRA2A—cerebellum—peripheral nervous system neoplasm	0.0011	0.00635	CbGeAlD
Zuclopenthixol—Domperidone—ABCB1—peripheral nervous system neoplasm	0.00106	0.124	CrCbGaD
Zuclopenthixol—Chlorpromazine—BCHE—peripheral nervous system neoplasm	0.00106	0.124	CrCbGaD
Zuclopenthixol—HTR2A—cerebellum—peripheral nervous system neoplasm	0.000937	0.0054	CbGeAlD
Zuclopenthixol—Nefazodone—ABCB1—peripheral nervous system neoplasm	0.000884	0.103	CrCbGaD
Zuclopenthixol—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000853	0.00492	CbGeAlD
Zuclopenthixol—Trazodone—ABCB1—peripheral nervous system neoplasm	0.000818	0.0954	CrCbGaD
Zuclopenthixol—Migraine—Doxorubicin—peripheral nervous system neoplasm	0.000682	0.000853	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00068	0.000851	CcSEcCtD
Zuclopenthixol—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000677	0.000846	CcSEcCtD
Zuclopenthixol—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000677	0.000846	CcSEcCtD
Zuclopenthixol—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00067	0.000837	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.00067	0.000837	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000668	0.000836	CcSEcCtD
Zuclopenthixol—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000665	0.000832	CcSEcCtD
Zuclopenthixol—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000665	0.000832	CcSEcCtD
Zuclopenthixol—Nausea—Topotecan—peripheral nervous system neoplasm	0.000665	0.000831	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000663	0.000829	CcSEcCtD
Zuclopenthixol—Fluphenazine—ABCB1—peripheral nervous system neoplasm	0.000662	0.0772	CrCbGaD
Zuclopenthixol—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.00066	0.000826	CcSEcCtD
Zuclopenthixol—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000659	0.000824	CcSEcCtD
Zuclopenthixol—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000659	0.000824	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000657	0.000821	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000653	0.000817	CcSEcCtD
Zuclopenthixol—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000652	0.000815	CcSEcCtD
Zuclopenthixol—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000651	0.000814	CcSEcCtD
Zuclopenthixol—Nausea—Melphalan—peripheral nervous system neoplasm	0.000651	0.000814	CcSEcCtD
Zuclopenthixol—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000644	0.000805	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000643	0.000804	CcSEcCtD
Zuclopenthixol—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000641	0.000801	CcSEcCtD
Zuclopenthixol—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.000641	0.000801	CcSEcCtD
Zuclopenthixol—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000641	0.000801	CcSEcCtD
Zuclopenthixol—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000641	0.000801	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.00064	0.0008	CcSEcCtD
Zuclopenthixol—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000639	0.000799	CcSEcCtD
Zuclopenthixol—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000638	0.000798	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000635	0.000794	CcSEcCtD
Zuclopenthixol—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000626	0.000783	CcSEcCtD
Zuclopenthixol—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000626	0.000783	CcSEcCtD
Zuclopenthixol—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000623	0.000779	CcSEcCtD
Zuclopenthixol—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000621	0.000776	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.00062	0.000775	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.00062	0.000775	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000619	0.000774	CcSEcCtD
Zuclopenthixol—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000615	0.000769	CcSEcCtD
Zuclopenthixol—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000614	0.000767	CcSEcCtD
Zuclopenthixol—Pain—Cisplatin—peripheral nervous system neoplasm	0.000613	0.000766	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000611	0.000764	CcSEcCtD
Zuclopenthixol—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000605	0.000757	CcSEcCtD
Zuclopenthixol—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000605	0.000757	CcSEcCtD
Zuclopenthixol—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000604	0.000755	CcSEcCtD
Zuclopenthixol—Chlorprothixene—ABCB1—peripheral nervous system neoplasm	0.000603	0.0703	CrCbGaD
Zuclopenthixol—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000597	0.000747	CcSEcCtD
Zuclopenthixol—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000595	0.000744	CcSEcCtD
Zuclopenthixol—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000593	0.000741	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000591	0.000739	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000591	0.000739	CcSEcCtD
Zuclopenthixol—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.00059	0.000737	CcSEcCtD
Zuclopenthixol—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000589	0.000737	CcSEcCtD
Zuclopenthixol—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000586	0.000732	CcSEcCtD
Zuclopenthixol—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000585	0.000732	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000584	0.00073	CcSEcCtD
Zuclopenthixol—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000584	0.00073	CcSEcCtD
Zuclopenthixol—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000582	0.000727	CcSEcCtD
Zuclopenthixol—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000577	0.000722	CcSEcCtD
Zuclopenthixol—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000577	0.000721	CcSEcCtD
Zuclopenthixol—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000576	0.00072	CcSEcCtD
Zuclopenthixol—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000572	0.000715	CcSEcCtD
Zuclopenthixol—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000571	0.000714	CcSEcCtD
Zuclopenthixol—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000569	0.000711	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000567	0.000709	CcSEcCtD
Zuclopenthixol—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000567	0.000708	CcSEcCtD
Zuclopenthixol—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000566	0.000708	CcSEcCtD
Zuclopenthixol—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000563	0.000703	CcSEcCtD
Zuclopenthixol—Pain—Etoposide—peripheral nervous system neoplasm	0.000561	0.000702	CcSEcCtD
Zuclopenthixol—Constipation—Etoposide—peripheral nervous system neoplasm	0.000561	0.000702	CcSEcCtD
Zuclopenthixol—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.00056	0.0007	CcSEcCtD
Zuclopenthixol—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.00056	0.0007	CcSEcCtD
Zuclopenthixol—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000556	0.000696	CcSEcCtD
Zuclopenthixol—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000555	0.000693	CcSEcCtD
Zuclopenthixol—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000553	0.000692	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000547	0.000684	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000546	0.000682	CcSEcCtD
Zuclopenthixol—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000545	0.000682	CcSEcCtD
Zuclopenthixol—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000542	0.000678	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000541	0.000677	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00054	0.000676	CcSEcCtD
Zuclopenthixol—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000539	0.000674	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000539	0.000673	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000537	0.000671	CcSEcCtD
Zuclopenthixol—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000536	0.00067	CcSEcCtD
Zuclopenthixol—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000535	0.000669	CcSEcCtD
Zuclopenthixol—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000534	0.000668	CcSEcCtD
Zuclopenthixol—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00053	0.000663	CcSEcCtD
Zuclopenthixol—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00053	0.000663	CcSEcCtD
Zuclopenthixol—Trifluoperazine—ABCB1—peripheral nervous system neoplasm	0.00053	0.0617	CrCbGaD
Zuclopenthixol—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000528	0.00066	CcSEcCtD
Zuclopenthixol—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000527	0.000659	CcSEcCtD
Zuclopenthixol—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.00052	0.000651	CcSEcCtD
Zuclopenthixol—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000519	0.000649	CcSEcCtD
Zuclopenthixol—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000519	0.000649	CcSEcCtD
Zuclopenthixol—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000515	0.000644	CcSEcCtD
Zuclopenthixol—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000514	0.000643	CcSEcCtD
Zuclopenthixol—Quetiapine—ABCB1—peripheral nervous system neoplasm	0.000514	0.0599	CrCbGaD
Zuclopenthixol—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000512	0.00064	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000512	0.00064	CcSEcCtD
Zuclopenthixol—Rash—Vincristine—peripheral nervous system neoplasm	0.000511	0.000639	CcSEcCtD
Zuclopenthixol—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000511	0.000638	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.00051	0.000638	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000509	0.000637	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000508	0.000635	CcSEcCtD
Zuclopenthixol—Headache—Vincristine—peripheral nervous system neoplasm	0.000508	0.000635	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000505	0.000631	CcSEcCtD
Zuclopenthixol—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.0005	0.000625	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000499	0.000624	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000498	0.000623	CcSEcCtD
Zuclopenthixol—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00049	0.000613	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000484	0.000605	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000484	0.000605	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000483	0.000604	CcSEcCtD
Zuclopenthixol—Nausea—Vincristine—peripheral nervous system neoplasm	0.000481	0.000602	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000481	0.000601	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000473	0.000592	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000472	0.00059	CcSEcCtD
Zuclopenthixol—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000471	0.000589	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000471	0.000589	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.00047	0.000588	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.00047	0.000588	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000468	0.000585	CcSEcCtD
Zuclopenthixol—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000465	0.000581	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000463	0.000579	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000462	0.000578	CcSEcCtD
Zuclopenthixol—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000456	0.00057	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000454	0.000568	CcSEcCtD
Zuclopenthixol—Rash—Cisplatin—peripheral nervous system neoplasm	0.000452	0.000565	CcSEcCtD
Zuclopenthixol—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000451	0.000565	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000451	0.000564	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000451	0.000564	CcSEcCtD
Zuclopenthixol—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000449	0.000562	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000448	0.00056	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000447	0.000559	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000445	0.000556	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000444	0.000556	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—peripheral nervous system neoplasm	0.000443	0.000553	CcSEcCtD
Zuclopenthixol—Clozapine—ABCB1—peripheral nervous system neoplasm	0.000442	0.0515	CrCbGaD
Zuclopenthixol—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000438	0.000548	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000435	0.000544	CcSEcCtD
Zuclopenthixol—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000434	0.000543	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000433	0.000541	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000428	0.000535	CcSEcCtD
Zuclopenthixol—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000426	0.000532	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000425	0.000531	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.00042	0.000525	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000418	0.000523	CcSEcCtD
Zuclopenthixol—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000417	0.000522	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000417	0.000522	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000417	0.000522	CcSEcCtD
Zuclopenthixol—Chlorpromazine—ABCB1—peripheral nervous system neoplasm	0.000416	0.0484	CrCbGaD
Zuclopenthixol—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000414	0.000518	CcSEcCtD
Zuclopenthixol—Rash—Etoposide—peripheral nervous system neoplasm	0.000414	0.000518	CcSEcCtD
Zuclopenthixol—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000414	0.000517	CcSEcCtD
Zuclopenthixol—Headache—Etoposide—peripheral nervous system neoplasm	0.000411	0.000514	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000411	0.000514	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000409	0.000512	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000407	0.000509	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000405	0.000507	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000405	0.000507	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000404	0.000506	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000404	0.000505	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000399	0.000498	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000396	0.000496	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000393	0.000492	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000391	0.000489	CcSEcCtD
Zuclopenthixol—Nausea—Etoposide—peripheral nervous system neoplasm	0.00039	0.000488	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000389	0.000487	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000387	0.000484	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000384	0.00048	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000383	0.00048	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000383	0.000478	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000381	0.000477	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000379	0.000474	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000376	0.000471	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000375	0.00047	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000375	0.000469	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000374	0.000468	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000374	0.000467	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000369	0.000461	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000368	0.00046	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000367	0.000459	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—peripheral nervous system neoplasm	0.000362	0.000453	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000362	0.000452	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000361	0.000451	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.00036	0.000451	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.00036	0.00045	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000359	0.000449	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000358	0.000447	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000356	0.000445	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000355	0.000444	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000354	0.000443	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000353	0.000441	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000351	0.000439	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000351	0.000439	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000434	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000344	0.00043	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000341	0.000426	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000335	0.000419	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000335	0.000419	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000418	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000333	0.000417	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000333	0.000416	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000332	0.000416	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000331	0.000414	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.00033	0.000413	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000329	0.000412	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000328	0.00041	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000327	0.000409	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000325	0.000406	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000324	0.000405	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.00032	0.0004	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000398	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000318	0.000397	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000317	0.000397	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—peripheral nervous system neoplasm	0.000315	0.000394	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000315	0.000394	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00031	0.000388	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000308	0.000385	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000306	0.000382	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000304	0.00038	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000303	0.000379	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.000379	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000301	0.000376	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.000375	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000296	0.00037	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000294	0.000368	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000294	0.000367	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.000364	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.000364	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000364	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000364	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000281	0.000351	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000278	0.000348	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000339	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000337	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000337	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000264	0.00033	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.00026	0.000326	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000252	0.000315	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000314	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.000306	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000243	0.000304	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000301	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000234	0.000293	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000291	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—peripheral nervous system neoplasm	0.000232	0.00029	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000232	0.00029	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—peripheral nervous system neoplasm	0.000231	0.000288	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.000282	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000273	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000217	0.000271	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000215	0.000269	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000215	0.000268	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.000267	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000253	CcSEcCtD
Zuclopenthixol—HTR2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.52e-05	0.00193	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.51e-05	0.00192	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.45e-05	0.00189	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.36e-05	0.00184	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	3.36e-05	0.00184	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.35e-05	0.00184	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.28e-05	0.0018	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	3.26e-05	0.00179	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.25e-05	0.00178	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—IFNB1—peripheral nervous system neoplasm	3.24e-05	0.00177	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.23e-05	0.00177	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.22e-05	0.00176	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.22e-05	0.00176	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.2e-05	0.00175	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.2e-05	0.00175	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.19e-05	0.00175	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.16e-05	0.00173	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.13e-05	0.00171	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—KNG1—peripheral nervous system neoplasm	3e-05	0.00164	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3e-05	0.00164	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.96e-05	0.00162	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.95e-05	0.00162	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.95e-05	0.00161	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.94e-05	0.00161	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	2.94e-05	0.00161	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	2.91e-05	0.00159	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.89e-05	0.00158	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.85e-05	0.00156	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.81e-05	0.00154	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.73e-05	0.00149	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—GNS—peripheral nervous system neoplasm	2.71e-05	0.00148	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.68e-05	0.00147	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.65e-05	0.00145	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—GNAS—peripheral nervous system neoplasm	2.63e-05	0.00144	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	2.6e-05	0.00142	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NME1—peripheral nervous system neoplasm	2.6e-05	0.00142	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.59e-05	0.00142	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.55e-05	0.0014	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.54e-05	0.00139	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.53e-05	0.00139	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—HGF—peripheral nervous system neoplasm	2.5e-05	0.00137	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—COX2—peripheral nervous system neoplasm	2.5e-05	0.00137	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.49e-05	0.00136	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.49e-05	0.00136	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.46e-05	0.00134	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.44e-05	0.00134	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.44e-05	0.00134	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.43e-05	0.00133	CbGpPWpGaD
Zuclopenthixol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.39e-05	0.00131	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.39e-05	0.00131	CbGpPWpGaD
Zuclopenthixol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.39e-05	0.00131	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.38e-05	0.0013	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.35e-05	0.00128	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.34e-05	0.00128	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.34e-05	0.00128	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.33e-05	0.00128	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.27e-05	0.00124	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.27e-05	0.00124	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.23e-05	0.00122	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.17e-05	0.00119	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.16e-05	0.00118	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.12e-05	0.00116	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.09e-05	0.00114	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.08e-05	0.00114	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.05e-05	0.00112	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.04e-05	0.00112	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.98e-05	0.00109	CbGpPWpGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.96e-05	0.00107	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.93e-05	0.00105	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.92e-05	0.00105	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.9e-05	0.00104	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.9e-05	0.00104	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.89e-05	0.00104	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.89e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.88e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.86e-05	0.00102	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.86e-05	0.00102	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.85e-05	0.00101	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.83e-05	0.000999	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.83e-05	0.000999	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.82e-05	0.000997	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.8e-05	0.000986	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.79e-05	0.000978	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.77e-05	0.000969	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.77e-05	0.000967	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.76e-05	0.000964	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.75e-05	0.000958	CbGpPWpGaD
Zuclopenthixol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.75e-05	0.000958	CbGpPWpGaD
Zuclopenthixol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.75e-05	0.000956	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.74e-05	0.000954	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.74e-05	0.000952	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.72e-05	0.000944	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.72e-05	0.00094	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.71e-05	0.000938	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.71e-05	0.000934	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.69e-05	0.000927	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.68e-05	0.000922	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.67e-05	0.000913	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.66e-05	0.000909	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.66e-05	0.000907	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.65e-05	0.000905	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ENO2—peripheral nervous system neoplasm	1.64e-05	0.000899	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.63e-05	0.000892	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.62e-05	0.000888	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.59e-05	0.000868	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.55e-05	0.000849	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.53e-05	0.000838	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.51e-05	0.000825	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.51e-05	0.000825	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.44e-05	0.000786	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.4e-05	0.000768	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—BCHE—peripheral nervous system neoplasm	1.39e-05	0.00076	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.38e-05	0.000754	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.38e-05	0.000753	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.33e-05	0.000728	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.32e-05	0.000725	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.32e-05	0.000721	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.31e-05	0.000716	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.31e-05	0.000715	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—TH—peripheral nervous system neoplasm	1.31e-05	0.000714	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.28e-05	0.000702	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.19e-05	0.000652	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.17e-05	0.000641	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.15e-05	0.00063	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.15e-05	0.000629	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.14e-05	0.000623	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.13e-05	0.000617	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.12e-05	0.000613	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.12e-05	0.000611	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—NRAS—peripheral nervous system neoplasm	1.1e-05	0.000601	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.1e-05	0.0006	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.09e-05	0.000596	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.08e-05	0.000594	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.08e-05	0.000593	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.07e-05	0.000586	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.07e-05	0.000584	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—GNAS—peripheral nervous system neoplasm	1.07e-05	0.000583	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.06e-05	0.000583	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.06e-05	0.000582	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.05e-05	0.000574	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ABCB1—peripheral nervous system neoplasm	1.05e-05	0.000572	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.04e-05	0.000572	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.03e-05	0.000562	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.02e-05	0.000558	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	9.98e-06	0.000546	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.95e-06	0.000545	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.89e-06	0.000541	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.79e-06	0.000536	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.77e-06	0.000535	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.71e-06	0.000531	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.59e-06	0.000525	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.32e-06	0.00051	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.16e-06	0.000501	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	9.06e-06	0.000496	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	9.04e-06	0.000495	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.91e-06	0.000488	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.63e-06	0.000472	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	8.5e-06	0.000465	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.41e-06	0.00046	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—TP53—peripheral nervous system neoplasm	8.4e-06	0.00046	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.29e-06	0.000454	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—HRAS—peripheral nervous system neoplasm	8.03e-06	0.00044	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.92e-06	0.000434	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.72e-06	0.000423	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.7e-06	0.000422	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.63e-06	0.000418	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.24e-06	0.000396	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	7.09e-06	0.000388	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.04e-06	0.000385	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7e-06	0.000383	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	6.94e-06	0.00038	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.93e-06	0.000379	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.92e-06	0.000378	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.91e-06	0.000378	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.82e-06	0.000373	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	6.81e-06	0.000373	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.8e-06	0.000372	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.79e-06	0.000372	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.78e-06	0.000371	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.66e-06	0.000365	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.63e-06	0.000363	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.57e-06	0.00036	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.4e-06	0.00035	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.34e-06	0.000347	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.3e-06	0.000345	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.19e-06	0.000339	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.06e-06	0.000332	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.02e-06	0.00033	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.96e-06	0.000326	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.51e-06	0.000301	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.47e-06	0.000299	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.38e-06	0.000294	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.37e-06	0.000294	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.35e-06	0.000293	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.27e-06	0.000288	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.15e-06	0.000282	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.13e-06	0.000281	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.07e-06	0.000277	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.06e-06	0.000277	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.01e-06	0.000274	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.96e-06	0.000272	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.96e-06	0.000272	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.93e-06	0.00027	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.92e-06	0.000269	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.89e-06	0.000268	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.89e-06	0.000268	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.88e-06	0.000267	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.87e-06	0.000267	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.82e-06	0.000264	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.78e-06	0.000262	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.68e-06	0.000256	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.61e-06	0.000252	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.55e-06	0.000249	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.48e-06	0.000245	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.47e-06	0.000245	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.46e-06	0.000244	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.44e-06	0.000243	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.38e-06	0.00024	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.21e-06	0.000231	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.16e-06	0.000228	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.13e-06	0.000226	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.09e-06	0.000224	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.08e-06	0.000223	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.07e-06	0.000223	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.03e-06	0.000221	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.01e-06	0.000219	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.87e-06	0.000212	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.81e-06	0.000209	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.8e-06	0.000208	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.73e-06	0.000204	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.72e-06	0.000204	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.56e-06	0.000195	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.47e-06	0.00019	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.18e-06	0.000174	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.13e-06	0.000171	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.12e-06	0.000171	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.06e-06	0.000168	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.04e-06	0.000166	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.99e-06	0.000164	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.99e-06	0.000163	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.93e-06	0.00016	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	2.88e-06	0.000157	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.85e-06	0.000156	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.72e-06	0.000149	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.69e-06	0.000147	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.64e-06	0.000145	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.64e-06	0.000144	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.59e-06	0.000142	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.4e-06	0.000132	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.87e-06	0.000103	CbGpPWpGaD
